GlobeNewswire
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
📈
AI Sentiment
Highly Positive
9/10
- Home
- ABOS
as of 03-03-2026 3:37pm EST
$3.32
+$0.02
+0.61%
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NEWTON |
| Market Cap: | 155.7M | IPO Year: | 2021 |
| Target Price: | $7.50 | AVG Volume (30 days): | 344.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.59 | EPS Growth: | -58.33 |
| 52 Week Low/High: | $0.86 - $3.30 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -2.04 | Index: | N/A |
| Free Cash Flow: | -86231000.0 | FCF Growth: | N/A |
AI-Powered ABOS Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 67.52%
67.52%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Acumen Pharmaceuticals Inc. (ABOS)
Meisner Derek M
Sell
Chief Legal Officer & Corp Sec
ABOS Jan 28, 2026
Avg Cost/Share
$3.00
Shares
2,671
Total Value
$8,017.27
Owned After
173,999
SEC Form 4
Meisner Derek M
Sell
Chief Legal Officer & Corp Sec
ABOS Jan 26, 2026
Avg Cost/Share
$3.00
Shares
15,085
Total Value
$45,262.54
Owned After
173,999
SEC Form 4
Meisner Derek M
Sell
Chief Legal Officer & Corp Sec
ABOS Jan 23, 2026
Avg Cost/Share
$1.90
Shares
5,633
Total Value
$10,717.91
Owned After
173,999
SEC Form 4
Meisner Derek M
Sell
Chief Legal Officer & Corp Sec
ABOS Jan 22, 2026
Avg Cost/Share
$1.84
Shares
1,054
Total Value
$1,939.36
Owned After
173,999
SEC Form 4
Barton Russell
Sell
Chief Operating Officer
ABOS Jan 22, 2026
Avg Cost/Share
$1.84
Shares
462
Total Value
$850.08
Owned After
205,092
SEC Form 4
OConnell Daniel Joseph
Sell
Chief Executive Officer
ABOS Jan 22, 2026
Avg Cost/Share
$1.88
Shares
2,689
Total Value
$5,065.54
Owned After
881,275
SEC Form 4
Siemers Eric
Sell
Chief Medical Officer
ABOS Jan 22, 2026
Avg Cost/Share
$1.82
Shares
895
Total Value
$1,628.90
Owned After
255,371
SEC Form 4
Meisner Derek M
Sell
Chief Legal Officer & Corp Sec
ABOS Jan 21, 2026
Avg Cost/Share
$1.81
Shares
2,247
Total Value
$4,063.25
Owned After
173,999
SEC Form 4
Barton Russell
Sell
Chief Operating Officer
ABOS Jan 21, 2026
Avg Cost/Share
$1.81
Shares
2,315
Total Value
$4,180.89
Owned After
205,092
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Meisner Derek M | ABOS | Chief Legal Officer & Corp Sec | Jan 28, 2026 | Sell | $3.00 | 2,671 | $8,017.27 | 173,999 | |
| Meisner Derek M | ABOS | Chief Legal Officer & Corp Sec | Jan 26, 2026 | Sell | $3.00 | 15,085 | $45,262.54 | 173,999 | |
| Meisner Derek M | ABOS | Chief Legal Officer & Corp Sec | Jan 23, 2026 | Sell | $1.90 | 5,633 | $10,717.91 | 173,999 | |
| Meisner Derek M | ABOS | Chief Legal Officer & Corp Sec | Jan 22, 2026 | Sell | $1.84 | 1,054 | $1,939.36 | 173,999 | |
| Barton Russell | ABOS | Chief Operating Officer | Jan 22, 2026 | Sell | $1.84 | 462 | $850.08 | 205,092 | |
| Zuga Matt | ABOS | CFO & Chief Business Officer | Jan 22, 2026 | Sell | $1.86 | 1,687 | $3,137.82 | 304,924 | |
| OConnell Daniel Joseph | ABOS | Chief Executive Officer | Jan 22, 2026 | Sell | $1.88 | 2,689 | $5,065.54 | 881,275 | |
| Siemers Eric | ABOS | Chief Medical Officer | Jan 22, 2026 | Sell | $1.82 | 895 | $1,628.90 | 255,371 | |
| Meisner Derek M | ABOS | Chief Legal Officer & Corp Sec | Jan 21, 2026 | Sell | $1.81 | 2,247 | $4,063.25 | 173,999 | |
| Barton Russell | ABOS | Chief Operating Officer | Jan 21, 2026 | Sell | $1.81 | 2,315 | $4,180.89 | 205,092 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 12, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLNov 12, 2025 · 100% conf.
AI Prediction SELL
1D
-0.49%
$1.94
5D
-9.49%
$1.76
20D
-6.38%
$1.83
Price: $1.95 Prob +5D: 0% AUC: 1.000
0001576885-25-000102
abos-202511120001576885FALSE1210-1220 Washington StreetSuite 210NewtonMassachusetts00015768852025-11-122025-11-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2025
Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-4055136-4108129 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
1210-1220 Washington Street, Suite 210 Newton, Massachusetts 02465 (Address of Principal Executive Offices)(Zip Code)
(617) 344-4190 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 par valueABOSThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On November 12, 2025, Acumen Pharmaceuticals, Inc. (the “Company”) reported financial results and business highlights for the quarter ended September 30, 2025. A copy of this press release (the “Earnings Press Release”) is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated by reference. The information in this Item 2.02 of this Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 7.01 Regulation FD Disclosure. On November 12, 2025, the Company posted an updated corporate presentation to its website at https://investors.acumenpharm.com/news-events/presentations, which the Company may use from time to time in communications or conferences. The corporate presentation was updated to reflect the Company’s cash, cash equivalents and marketable securities balance as of September 30, 2025. A copy of the corporate presentation is attached as Exhibit 99.2 to this Report.
The information in this Item 7.01 of this Report (including Exhibit 99.2), is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company’s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
Item 9.01 Financial Statements and Exhibits. (d).Exhibits
Exhibit No.Description 99.1Earnings Press Release, dated November 12, 2025
99.2Corporate Presentation, dated November 12, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Acumen Pharmaceuticals, Inc.
Dated: November 12, 2025 By:/s/ Matthew Zuga Matthew Zuga Chief Financial Officer and Chief Business Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 12, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 12, 2025
0001576885-25-000091
abos-202508120001576885FALSE1210-1220 Washington StreetSuite 210NewtonMassachusetts00015768852025-08-122025-08-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025
Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-4055136-4108129 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
1210-1220 Washington Street, Suite 210 Newton, Massachusetts 02465 (Address of Principal Executive Offices)(Zip Code)
(617) 344-4190 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 par valueABOSThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On August 12, 2025, Acumen Pharmaceuticals, Inc. (the “Company”) reported financial results and business highlights for the quarter ended June 30, 2025. A copy of this press release (the “Earnings Press Release”) is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated by reference. The information in this Item 2.02 of this Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 7.01 Regulation FD Disclosure. On August 12, 2025, the Company posted an updated corporate presentation to its website at https://investors.acumenpharm.com/news-events/presentations, which the Company may use from time to time in communications or conferences. The corporate presentation was updated to reflect the Company’s cash, cash equivalents and marketable securities balance as of June 30, 2025. A copy of the corporate presentation is attached as Exhibit 99.2 to this Report.
The information in this Item 7.01 of this Report (including Exhibit 99.2), is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company’s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
Item 9.01 Financial Statements and Exhibits. (d).Exhibits
Exhibit No.Description 99.1Earnings Press Release, dated August 12, 2025
99.2Corporate Presentation, dated August 12, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Acumen Pharmaceuticals, Inc.
Dated: August 12, 2025 By:/s/ Matthew Zuga Matthew Zuga Chief Financial Officer and Chief Business Officer
2025 Q1 Q1 2025 Earnings
8-K May 13, 2025
2025
Q1
Q1 2025 Earnings
8-KMay 13, 2025
0001576885-25-000062
abos-202505130001576885FALSE00015768852025-05-132025-05-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025
Acumen Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-4055136-4108129 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
1210-1220 Washington Street, Suite 210 Newton, Massachusetts 02465 (Address of Principal Executive Offices)(Zip Code)
(617) 344-4190 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 par valueABOSThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On May 13, 2025, Acumen Pharmaceuticals, Inc. (the “Company”) reported financial results and business highlights for the quarter ended March 31, 2025. A copy of this press release (the “Earnings Press Release”) is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated by reference. The information in this Item 2.02 of this Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 7.01 Regulation FD Disclosure. On May 13, 2025, the Company posted an updated corporate presentation to its website at https://investors.acumenpharm.com/news-events/presentations, which the Company may use from time to time in communications or conferences. The corporate presentation was updated to reflect updates to the Company’s leadership team and that, as of March 31, 2025, the Company’s cash, cash equivalents and marketable securities balance was approximately $198 million, based upon which the Company projects that its cash, cash equivalents and marketable securities will be sufficient to support the Company’s operations into early 2027. A copy of the corporate presentation is attached as Exhibit 99.2 to this Report.
The information in this Item 7.01 of this Report (including Exhibit 99.2), is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company’s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
Item 9.01 Financial Statements and Exhibits. (d).Exhibits
Exhibit No.Description 99.1Earnings Press Release, dated May 13, 2025
99.2Corporate Presentation, dated May 13, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Acumen Pharmaceuticals, Inc.
Dated: May 13, 2025By:
Latest Acumen Pharmaceuticals Inc. News
ABOS Breaking Stock News: Dive into ABOS Ticker-Specific Updates for Smart Investing
Compare ABOS vs Leading Stocks
See how ABOS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ABOS Acumen Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.